A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
The goal of this clinical research study is to measure the blood levels of the study drug ASTX727 (a combination of cedazuridine and decitabine) when given to patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) to learn how patients respond to the drug. Researchers also want to learn about the long-term effects of the study drug.
Treatment Location: N/A
IRB Review and Approval Date: 02/07/2018
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: